Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Wirtz HS"'
Publikováno v:
Clinical Epidemiology, Vol Volume 15, Pp 765-773 (2023)
Matthew D Galsky,1 Heidi S Wirtz,2 Brian Bloudek,3 Zsolt Hepp,2 Mallory Farrar,2 Jack Timmons,3 Enrique Lenero,4 Thomas Powles5 1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Seagen Inc., Bothell, WA, USA; 3Curt
Externí odkaz:
https://doaj.org/article/51f72ee1f82c4a8a8b39d1c679df8e62
Publikováno v:
Clinical Epidemiology, Vol Volume 14, Pp 1375-1386 (2022)
Brian Bloudek,1 Heidi S Wirtz,2 Zsolt Hepp,2 Jack Timmons,1 Lisa Bloudek,1 Caroline McKay,3 Matthew D Galsky4 1Curta Inc., Seattle, WA, USA; 2Seagen Inc., Bothell, WA, USA; 3Astellas Pharma Global Development, Inc., Northbrook, IL, USA; 4Tisch Cancer
Externí odkaz:
https://doaj.org/article/d72735e9e396462e9a5a6a49363c5649
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wirtz HS; Seagen Inc, 21717 30th Dr SE, Bothell, WA 98021. Email: hwirtz@seagen.com., Hepp Z, Grewal S, Wright P, Fuldeore R, Tomicki S, Hirsch J, Dieguez G, Blakely LJ
Publikováno v:
The American journal of managed care [Am J Manag Care] 2023 May 01; Vol. 29 (5), pp. e136-e142. Date of Electronic Publication: 2023 May 01.
Autor:
Alimohamed N; Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada., Grewal S; Seagen Inc., Bothell, WA 98021, USA., Wirtz HS; Seagen Inc., Bothell, WA 98021, USA., Hepp Z; Seagen Inc., Bothell, WA 98021, USA., Sauvageau S; Seagen Canada, Mississauga, ON L5N 1W1, Canada., Boyne DJ; Oncology Outcomes (O2), Calgary, AB T2N 4N2, Canada., Brenner DR; Oncology Outcomes (O2), Calgary, AB T2N 4N2, Canada., Cheung WY; Oncology Outcomes (O2), Calgary, AB T2N 4N2, Canada., Jarada TN; Oncology Outcomes (O2), Calgary, AB T2N 4N2, Canada.
Publikováno v:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Oct 12; Vol. 29 (10), pp. 7587-7597. Date of Electronic Publication: 2022 Oct 12.
Autor:
McHorney CA; Patient Centered Research, Evidera, Bethesda, MD, United States of America., Mansukhani SG; Patient Centered Research, Evidera, Bethesda, MD, United States of America., Anatchkova M; Patient Centered Research, Evidera, Bethesda, MD, United States of America., Taylor N; Patient Centered Research, Evidera, Bethesda, MD, United States of America., Wirtz HS; Global Health Economics, Amgen, Thousand Oaks, CA, United States of America., Abbasi S; Global Health Economics, Amgen, Thousand Oaks, CA, United States of America., Battle L; Patient Author from Cincinnati, Cincinnati, OH, United States of America., Desai NR; Yale School of Medicine, New Haven, CT, United States of America., Globe G; Global Health Economics, Amgen, Thousand Oaks, CA, United States of America.
Publikováno v:
PloS one [PLoS One] 2021 Mar 11; Vol. 16 (3), pp. e0248240. Date of Electronic Publication: 2021 Mar 11 (Print Publication: 2021).
Autor:
Di Tanna GL; Statistics Division, The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. gditanna@georgeinstitute.org.au.; The George Institute for Global Health, Level 5, 1 King St, Newtown, NSW, 2042, Australia. gditanna@georgeinstitute.org.au., Urbich M; Amgen (Europe) GmbH, Global Value & Access, Modeling Center of Excellence, Rotkreuz, Switzerland., Wirtz HS; Amgen Inc, Global Health Economics, Thousand Oaks, CA, USA., Potrata B; Pharmerit - an OPEN Health company, Rotterdam, The Netherlands., Heisen M; Pharmerit - an OPEN Health company, Rotterdam, The Netherlands., Bennison C; Pharmerit - an OPEN Health company, York, UK., Brazier J; Health Economics and Decision Science, University of Sheffield, Sheffield, UK., Globe G; Amgen Inc, Global Health Economics, Thousand Oaks, CA, USA.
Publikováno v:
PharmacoEconomics [Pharmacoeconomics] 2021 Feb; Vol. 39 (2), pp. 211-229. Date of Electronic Publication: 2020 Nov 30.
Autor:
Urbich M; Amgen (Europe) GmbH, Global Health Economics, Suurstoffi 22, 6343, Rotkreuz, Switzerland. murbich@amgen.com., Globe G; Amgen Inc, Global Health Economics, Thousand Oaks, CA, USA., Pantiri K; Pharmerit - an OPEN Health Company, Rotterdam, The Netherlands., Heisen M; Pharmerit - an OPEN Health Company, Rotterdam, The Netherlands., Bennison C; Pharmerit - an OPEN Health Company, York, UK., Wirtz HS; Amgen Inc, Global Health Economics, Thousand Oaks, CA, USA., Di Tanna GL; The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Publikováno v:
PharmacoEconomics [Pharmacoeconomics] 2020 Nov; Vol. 38 (11), pp. 1219-1236.
Autor:
Di Tanna GL; The George Institute for Global Health, Sydney, Australia., Chen S; The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA., Bychenkova A; Global Health Economics, Amgen Inc., Uxbridge, UK., Wirtz HS; Global Health Economics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320‑1799, USA., Burrows KL; Envision Pharma Group, Horsham, UK., Globe G; Global Health Economics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320‑1799, USA. gglobe@amgen.com.
Publikováno v:
PharmacoEconomics - open [Pharmacoecon Open] 2020 Sep; Vol. 4 (3), pp. 397-401.